Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells

Immunology

Volumn 133, Issue 1, 2011, Pages 105-114

  Destro, Federica ^a   Sforza, Fabio ^a   Sicurella, Mariaconcetta ^a   Marescotti, Diego ^a   Gallerani, Eleonora ^a   Baldisserotto, Anna ^b   Marastoni, Mauro ^b   Gavioli, Riccardo ^a  

^a Department of Biochemistry and Molecular Biology ^*  (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Burkitt's lymphoma; Cytotoxic T lymphocytes; Epstein Barr virus; Epstein Barr virus nuclear antigen 1; Proteasome inhibitors

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BUTABINDIDE; CHLOROQUINE; CHYMOTRYPSIN; EPITOPE; EPOXOMICIN; EPSTEIN BARR VIRUS ANTIGEN 1; HLA ANTIGEN CLASS 1; HLA B35 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; PROTEASOME INHIBITOR; RAPAMYCIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; BURKITT LYMPHOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; INHIBITION KINETICS; LYMPHOCYTE TRANSFORMATION; LYMPHOMA CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN TARGETING;

ANTIGEN PRESENTATION; BLOTTING, WESTERN; BORONIC ACIDS; BURKITT LYMPHOMA; CELL LINE; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LEUPEPTINS; OLIGOPEPTIDES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79953315562     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03416.x     Document Type: Article

References (38)

1. Kieff E, Leibowitz D. Epstein-Barr virus and its replication. In: Fields BM, Knipe DN, eds. Virology, 2nd edn, Vol. 2. New York: Raven Press, 1990:1889-920.
2. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998; 16:323-58.
3. Gavioli R, Kurilla MG, de Campos-Lima PO, Wallace LE, Dolcetti R, Murray RJ, Rickinson AB, Masucci MG. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 1993; 67:1572-8.
4. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992; 176:169-76.
5. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176:157-68.
6. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15:405-31.
7. Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med 1996; 184:1801-13.
8. Gavioli R, De Campos-Lima PO, Kurilla MG, Kieff E, Klein G, Masucci MG. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci U S A 1992; 89:5862-6.
9. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997; 7:791-802.
10. Lee SP, Brooks JM, Al-Jarrah H et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med 2004; 199:1409-20.
11. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 2004; 199:1421-31.
12. + T lymphocytes. J Exp Med 2004; 199:459-70.
13. Marescotti D, Destro F, Baldisserotto A, Marastoni M, Coppotelli G, Masucci M, Gavioli R. Characterization of an human leukocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope. Immunology 2010; 129:386-95.
14. Apcher S, Komarova A, Daskalogianni C, Yin Y, Malbert-Colas L, Fåhraeus R. mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1. J Virol 2009; 83:1289-98.
15. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 2003; 301:1371-4.
16. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (London) 1995; 375:685-8.
17. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 1997; 94:12616-21.
18. + T cells for the treatment of EBV-related tumors. J Immunol 2010; 184:5895-902.
19. Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925-35.
20. + T cell response: lessons from the EBV nuclear antigen EBNA1. J Immunol 2000; 165:7078-87.
21. Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol 2001; 3:283-8.
22. Gavioli R, Gallerani E, Fortini C et al. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 2004; 173:3838-43.
23. Gavioli R, Guerrini R, Masucci MG, Tomatis R, Traniello S, Marastoni M. High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes. FEBS Lett 1998; 421:95-9.
24. Micheletti F, Guerrini R, Formentin A et al. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies. Eur J Immunol 1999; 29:2579-89.
25. Masucci MG, Torsteindottir S, Colombani J, Brautbar C, Klein E, Klein G. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A 1987; 84:4567-71.
26. Masucci MG, Stam NJ, Torsteinsdottir S, Neefjes JJ, Klein G, Ploegh HL. Allele-specific down-regulation of MHC class I antigens in Burkitt lymphoma lines. Cell Immunol 1989; 120:396-400.
27. Frisan T, Zhang QJ, Levitskaya J, Coram M, Kurilla MG, Masucci MG. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells. Int J Cancer 1996; 68:251-8.
28. Rowe M, Khanna R, Jacob CA et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995; 25:1374-84.
29. Frisan T, Levitsky V, Polack A, Masucci MG. Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. J Immunol 1998; 160:3281-9.
30. Vinitsky A, Antón LC, Snyder HL, Orlowski M, Bennink JR, Yewdell JW. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing? J Immunol 1997; 159:554-64.
31. Luckey CJ, King GM, Marto JA et al. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J Immunol 1998; 161:112-21.
32. Valmori D, Gileadi U, Servis C, Dunbar PR, Cerottini JC, Romero P, Cerundolo V, Lévy F. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med 1999; 189:895-906.
33. Schwarz A, Beissert S, Grosse-Heitmeyer K, Gunzer M, Bluestone JA, Grabbe S, Schwarz T. Evidence for functional relevance of CTLA-4 in ultraviolet-radiation-induced tolerance. J Immunol 2000; 165:1824-31.
34. Gavioli R, Vertuani S, Masucci MG. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors. Int J Cancer 2002; 101:532-8.
35. + T cells that poorly kill EBV-infected cells. Viral Immunol 2002; 15:213-25.
36. Daskalogianni C, Apcher S, Candeias MM, Naski N, Calvo F, Fåhraeus R. Gly-Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing. J Biol Chem 2008; 283:30090-100.
37. Kawada J, Zou P, Mazitschek R, Bradner JE, Cohen JI. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem 2009; 284:17102-9.
38. Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol 2007; 81:10029-36.